Last reviewed 2026-04-23 · How we verify

Placebo (for Otamixaban)

Sanofi · Phase 3 active Small molecule

Placebo (for Otamixaban) is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication).

Placebo is an inert control substance with no active pharmacological mechanism.

Placebo is an inert control substance with no active pharmacological mechanism. Used for Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication).

At a glance

Generic name	Placebo (for Otamixaban)
Sponsor	Sanofi
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

Placebo serves as a negative control in clinical trials and contains no active pharmaceutical ingredient. It is used to establish baseline efficacy and safety profiles by comparison with the active drug being tested. In this case, it is the control arm for Otamixaban, a Factor Xa inhibitor.

Approved indications

Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication)

Common side effects

No common side effects on file.

Key clinical trials

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo (for Otamixaban) CI brief — competitive landscape report
Placebo (for Otamixaban) updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about Placebo (for Otamixaban)

What is Placebo (for Otamixaban)?

Placebo (for Otamixaban) is a Small molecule drug developed by Sanofi, indicated for Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication).

How does Placebo (for Otamixaban) work?

Placebo is an inert control substance with no active pharmacological mechanism.

What is Placebo (for Otamixaban) used for?

Placebo (for Otamixaban) is indicated for Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication).

Who makes Placebo (for Otamixaban)?

Placebo (for Otamixaban) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is Placebo (for Otamixaban) in?

Placebo (for Otamixaban) is in Phase 3.

Manufacturer: Sanofi — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Control arm in Phase 3 trials for Otamixaban (acute coronary syndrome or related cardiovascular indication)
Compare: Placebo (for Otamixaban) vs similar drugs
Pricing: Placebo (for Otamixaban) cost, discount & access